We appreciate the interest of Yaghjyan et al. in our study that determined the association between overall quality of dietary intake and cancer-specific and overall mortality among cancer survivors. We have already acknowledged most of the concerns Yaghjyan et al. raised as limitations of our study accompanied by a statement for cautious interpretation given these limitations: Dietary intake data in the NHANES are self-reported; the Healthy Eating Index (HEI) scores in our analysis are based on only one 24-hour dietary recall and may not represent habitual dietary behavior; information on cancer was limited to diagnosis of cancer and cancer type (eg, it was not possible to differentiate skin cancer types); stage of cancer was not available. We also acknowledged that our results may be confounded due to reasons other than diet, such as lifestyle (eg, physical activity), cancer surveillance, and treatment. We hope that future releases of NHANES will include data on the variables such as cancer stage, treatment, and cancer type to allow for adjustment of these confounders in future studies.
We would like to provide some additional clarification regarding the association between saturated fat intake and mortality. Most published studies compare an increasing amount of saturated fat intake with the highest limits beyond the recommended intake of less than 10% of total calorie intake. However, in our analysis we compared the mortality risk for patients in the highest vs lowest quartiles. In calculation of the HEI scores, zero is assigned for zero servings, and the maximum score indicates that the recommended servings were reached. Thus, patients in the highest quartile were those consuming saturated fat equal to or near to the recommended serving of saturated fat. It is likely that eating within the recommended limit might be associated with a decrease in overall and cancer-specific mortality. For instance, in a study by Richman et al. (1), the hazard ratio for all-cause mortality for prostate cancer patients was statistically non-significant (hazard ratio ¼ 0.94; 95% confidence interval ¼ 0.77 to 1.15) for patients with 8.2% of their intake from saturated fat compared with 6.2%; however, with progressively increased consumption, the likelihood of mortality increased and became statistically significant for 12% (above the recommended intake of 10%).
In summary, despite several limitations, our study provides strong early evidence supporting a role of diet for improving outcomes among cancer survivors.
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